United Guardian (UG) Net Income towards Common Stockholders (2010 - 2026)
United Guardian's (UG) quarterly Net Income towards Common Stockholders came in at $622448.0 in Q2 2026, down 0.7% year-over-year from $626826.0 in Q2 2025, and down 23.99% quarter-over-quarter from $818902.0 in Q1 2026.
Analysis
United Guardian (UG) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
United Guardian has disclosed Net Income towards Common Stockholders across 17 years of filings, most recently posting $622448.0 for Q2 2026.
- In Q2 2026, Net Income towards Common Stockholders fell 0.7% year-over-year to $622448.0; the TTM figure through Jun 2026 stood at $2.3 million (down 6.29% YoY), while the FY2025 annual figure was $2.1 million, down 32.65% from the prior year.
- Net Income towards Common Stockholders came in at $622448.0 for Q2 2026 at United Guardian, down from $818902.0 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $925442.0 in Q1 2024 to a low of $128427.0 in Q3 2022.
- Average Net Income towards Common Stockholders over 5 years is $626950.2, with a median of $638201.0 recorded in 2025.
- Year-over-year, Net Income towards Common Stockholders plunged 86.37% in 2022 and jumped 388.03% in 2023.
- Over 5 years, Net Income towards Common Stockholders stood at $753749.0 in 2022, then declined by 3.92% to $724183.0 in 2023, then plunged by 40.58% to $430295.0 in 2024, then surged by 50.96% to $649576.0 in 2025, then dropped by 4.18% to $622448.0 in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $622448.0 in Q2 2026, $818902.0 in Q1 2026, and $649576.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 647.22 Bn | 626.46 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 440.28 Bn | 433.71 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 364.30 Bn | 357.16 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 268.44 Bn | 260.75 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Pfizer | 158.60 Bn | 146.90 Bn | 10.94 Bn | -238.00 Mn |
| 6 | Sanofi | 52.56 Bn | 45.18 Bn | 10.79 Bn | 398.69 Mn |
| 7 | Revolution Medicines | 44.31 Bn | 44.31 Bn | - | -644.37 Mn |
| 8 | Incyte | 24.98 Bn | 20.45 Bn | 1.57 Bn | 585.61 Mn |
| 9 | United Therapeutics | 21.16 Bn | 18.49 Bn | 683.80 Mn | 333.00 Mn |
| 10 | United Guardian | 32.71 Mn | 23.12 Mn | 1.55 Mn | 622,448.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 622,448.00 |
| Mar 31, 2026 | 818,902.00 |
| Dec 31, 2025 | 649,576.00 |
| Sep 30, 2025 | 172,041.00 |
| Jun 30, 2025 | 626,826.00 |
| Mar 31, 2025 | 560,895.00 |
| Dec 31, 2024 | 430,295.00 |
| Sep 30, 2024 | 796,793.00 |
| Jun 30, 2024 | 903,084.00 |
| Mar 31, 2024 | 925,442.00 |
| Dec 31, 2023 | 724,183.00 |
| Sep 30, 2023 | 626,756.00 |
| Jun 30, 2023 | 461,094.00 |
| Mar 31, 2023 | 705,778.00 |
| Dec 31, 2022 | 753,749.00 |
| Sep 30, 2022 | 128,427.00 |
| Jun 30, 2022 | 467,350.00 |
| Mar 31, 2022 | 911,465.00 |
| Dec 31, 2021 | 1.05 Mn |
| Sep 30, 2021 | 942,571.00 |